Table 3.
Transgenesis | ||||
Subunit targeted |
Type of modification |
Cell type targeted |
Functions modified/studied | References |
Kir6.2 | Pore mutant | Pancreatic | Pancreatic β-cell function | [108–109] |
Kir6.1, Kir6.2 | Pore mutant | Cardiac | Exercise stress, KATP activity | [59] |
Kir6.2 | ATP insensitive | Cardiac | Cardiovascular function | [110] |
SUR1, SUR2A | Overexpression | Cardiac | Cardiovascular function | [111] |
Kir6 | Pore mutant | Endothelial | Hypertension, endothelial endothelin-1 release | [112] |
Kir6 | Pore mutant | Smooth muscle | Energetics | [113] |
Gene targeting | ||||
Subunit targeted |
Total number of exons |
Exon(s) targeted |
Functions modified/studied | References |
Kir6.1 | 3 | 3rd | Vascular | [114] |
Kir6.2 | 1 | 1st | Stress, ischemic preconditioning, insulin release | [115–117] |
SUR1 | 39 | 1st | Insulin release | [118] |
SUR1 | 39 | 2nd | Insulin release, cardiac ischemia, atrial KATP | [52, 119–120] |
SUR2 | 41 | 12th to 16th | Vascular, cardiac ischemia | [65, 121–123] |
Exons are numbered according to the cited references.